24078-25-9

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 17100-58-2 4-bromo-2-methylbenzyl alcohol 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 530145-22-3 methyl 4-[(acetyloxy)methyl]-3-methylbenzoate 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 
• 5471-81-8 methyl 4-iodo-3-methylbenzoate 
• 24078-24-8 methyl 4-formyl-3-methylbenzoate 
• 148547-19-7 4-Bromo-3-methylbenzoic acid methyl ester 

Downstream Products

• 104447-92-9 4-bromomethyl-3-methylbenzoic acid methyl ester 
• 916913-98-9 methyl 4-{[(6-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}-2,3-dihydro-1H-inden-5-yl)oxy]methyl}-3-methylbenzoate 
• 459841-58-8 3-methyl-4-[6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid 
• 916913-69-4 methyl 4-{[2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}-5-(trifluoromethyl)phenoxy]methyl}-3-methylbenzoate 
• 916914-02-8 methyl 4-[({6-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]-3-methylbenzoate 
• 916913-89-8 methyl 3-methyl-4-{[(6-{[(5-methyl-2-furyl)sulfonyl]amino}-2,3-dihydro-1H-inden-5-yl)oxy]methyl}benzoate 
• 459841-25-9 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-5-dimethylphenoxymethyl]benzoic acid methyl ester 
• 459841-26-0 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-5-dimethylphenoxymethyl]benzoic acid 
• 916914-01-7 methyl 4-({2-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-4,5-dimethylphenoxy}methyl)-3-methylbenzoate 
• 916913-93-4 methyl 3-methyl-4-[({6-[(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]benzoate 

Relevant academic research and scientific papers

HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS

The present invention relates to compounds of general formula (I), wherein D 1 to D 3, -A-, n, R 1, R 2, Y 1, L and y2 are defined as in claim 1, which have valuable pharmacological propert

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS

Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

Optimization of sulfonamide derivatives as highly selective EP1 receptor antagonists

A series of 4-[(2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}phenoxy)methyl]benzoic acids and 4-({2-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy}methyl)benzoic acids were synthesized and evaluated for their EP receptor affinities and EP1 receptor anta

NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF

A benzophenone derivative represented by the following formula: whereinR1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R2 represents, for example, a carboxyl group optionally protected with alkyl;R3 represents, for example, an optionally protected hydroxyl group; R4 represents, for example, an optionally substituted cycloalkyloxy group; and R5 represents, for example, a hydrogen atom, ???or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.